12 completed, 5 terminated, 4 active not recruiting, 2 recruiting. 24 Phase 3.
By phase and status
Follow BeiGene: new trials by email
Trials (filtered) newest first · largest first
All 24 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease Tislelizumab, Blood sampling, Placebo - Cancer, Lung Cancer Phase 3 Recruiting 717 2025-04-16 2025-05-13
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer Tislelizumab, Adjuvant chemotherapy - Colorectal Cancer, Microsatellite Instability High Phase 3 Recruiting 180 2024-11-01 2024-11-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma Sitravatinib, Tislelizumab, sitravatinib-matching placebo - Hepatocellular Carcinoma Phase 3 Withdrawn 2023-06-30 2023-06-07
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Tislelizumab, Docetaxel, Sitravatinib - Non-Small Cell Lung Cancer (NSCLC) Phase 3 Terminated 377 2021-07-27 2025-06-29
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer Tislelizumab, Durvalumab, Ociperlimab - Non Small Cell Lung Cancer Phase 3 Terminated 63 2021-06-17 2024-10-31
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer Tislelizumab, Ociperlimab, Pembrolizumab - Non-small Cell Lung Cancer, NSCLC Phase 3 Terminated 669 2021-05-24 2026-05-12
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma Tislelizumab, Salvage Chemotherapy - Classical Hodgkin Lymphoma Phase 3 Terminated 3 2020-12-14 2026-03-02
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) Tislelizumab, Cisplatin injection, Paclitaxel injection - Non Small Cell Lung Cancer Phase 3 Active not recruiting 453 2020-05-29 2026-03-18
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer Tislelizumab, Cisplatin, Carboplatin - Small Cell Lung Cancer Phase 3 Completed 457 2019-07-22 2025-02-28
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma Tislelizumab, Placebo, Paclitaxel - Esophageal Squamous Cell Carcinoma (ESCC) Phase 3 Completed 370 2019-06-11 2026-04-13
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma Tislelizumab, Placebo, Cisplatin - Urothelial Carcinoma Phase 3 Active not recruiting 420 2019-05-29 2026-06-22
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo - Carcinoma, Non-Small-Cell Lung Phase 3 Terminated 1 2019-05-22 2020-07-15
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) Tislelizumab, Placebo, Gemcitabine - Recurrent or Metastatic Nasopharyngeal Cancer Phase 3 Completed 263 2019-03-27 2025-01-31
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Tislelizumab, Placebo, Cisplatin - Gastric, or Gastroesophageal Junction Adenocarcinoma Phase 3 Completed 997 2018-12-13 2025-02-14
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Cisplatin, Oxaliplatin, Fluorouracil (5-FU) - Esophageal Squamous Cell Carcinoma (ESCC) Phase 3 Completed 649 2018-12-11 2025-07-29
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia Zanubrutinib, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Phase 3 Completed 652 2018-11-01 2025-03-30
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer Tislelizumab, Paclitaxel, Nab-paclitaxel - Non-Small Cell Lung Cancer Phase 3 Completed 360 2018-07-30 2024-10-26
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer Tislelizumab, Cisplatin, Carboplatin - Non-Small Cell Lung Cancer Phase 3 Completed 334 2018-07-23 2025-02-04
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer Pamiparib capsule, Placebo capsule - Ovarian Cancer Phase 3 Active not recruiting 224 2018-05-14 2026-03-16
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) Phase 3 Completed 512 2018-01-26 2024-10-26
Showing 20 of 24. Sign in to see all of them.
Conditions studied Carcinoma, Non-Small-Cell Lung (8) · Esophageal Squamous Cell Carcinoma (3) · Carcinoma, Hepatocellular (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Neoplasm Metastasis (2) · Recurrence (2) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1)
Interventions tislelizumab (20) · Cisplatin (8) · Carboplatin (5) · Paclitaxel (5) · Docetaxel (3) · zanubrutinib (3) · Capecitabine (2) · Chemoradiotherapy (2) · Fluorouracil (2) · Gemcitabine (2) · Oxaliplatin (2) · Pemetrexed (2) · Radiotherapy (2) · ibrutinib (2) · sitravatinib (2)
Countries China (21) · France (10) · Spain (10) · Taiwan (10) · United States (10) · Italy (9) · Poland (9) · United Kingdom (8) · Australia (7) · Germany (7) · Japan (6) · Russia (6) · Belgium (5) · Czechia (5) · South Korea (5)
Top investigators Caicun Zhou, PhD (1) · Dingwei Ye, MD (1) · Jin Wang, MD (1) · Marie Nguyen, MD (1) · Pei-Rong Ding, M.D. (1) · Weihu Wang, MD (1) · Xia Zhao, MD (1) · Zefen Xiao, MD (1)
Results publications PMID 38502198 , PMID 40373876 , PMID 29869556 , PMID 30969136 , PMID 31875923 , PMID 32207333 , PMID 33054121 , PMID 33509647 , PMID 34033975 , PMID 34269067 , PMID 35333492 , PMID 35442766 , PMID 35785595 , PMID 35810754 , PMID 36184068 , PMID 37080222 , PMID 37207654 , PMID 37478390 , PMID 37587845 , PMID 37752878 , PMID 37752892 , PMID 37796513 , PMID 37846080 , PMID 38052215 , PMID 38088119 , PMID 38240916 , PMID 38305608 , PMID 38414510 , PMID 38460751 , PMID 38598745 , PMID 38671587 , PMID 38806195 , PMID 38888616 , PMID 38923910 , PMID 39072392 , PMID 39316666 , PMID 39435268 , PMID 39482589 , PMID 39581197 , PMID 39626287 , PMID 39647999 , PMID 39738721 , PMID 39853273 , PMID 40075024 , PMID 40075025 , PMID 40179324 , PMID 40448577 , PMID 40528576 , PMID 40924923 , PMID 40944848
NIH funding 2018 (5) , 2017 (3) , 2023 (2) , 2016 (1)